Tarvacin(TM) Anti-Viral Hepatitis C Clinical Program in Acceleration (Hep C Treatment)

Tarvacin(TM) Anti-Viral Hepatitis C Clinical Program in Acceleration
RxPG - "The initial success of our efforts to accelerate the HCV clinical trial program for Tarvacin Anti-Viral is gratifying in view of Tarvacin's promise as an important new treatment option for a number of viral infections, including chronic hepatitis C

Viral Hepatitis and HIV Coinfection
Medscape News - In Western countries, chronic HBV infection affects 5% to 10% of HIV-positive individuals. However, a larger proportion of the HIV-infected population has been exposed to HBV in the past. Isolated hepatitis B core antibody (anti-HBc) is more common

FDA Grants Fast Track Designation To Oral HCV Protease Inhibitor SCH
Medical News Today - Schering-Plough today reported that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its investigational oral hepatitis C protease inhibitor (SCH 503034), currently in Phase II clinical development for the treatment

Schering-Plough Drug Gets Fast Track
MSN MoneyCentral - KENILWORTH, N.J. (AP) - Drug maker Schering-Plough Corp. said Monday that regulators granted "fast track" status to its experimental hepatitis C treatment. The Food and Drug Administration gives the fast track label -- which sometimes helps speed the